Janssen Gives Next-Gen CAR-Ts Another Shot After Fate Deal’s Collapse

J&J Inks New $245m Partnership With Cellular Biomedicine

 
• By Alaric DeArment

A new collaboration with Cellular Biomedicine includes a CD19/CD20-directed bispecific CAR-T in Phase I development for B-cell non-Hodgkin lymphomas.

Janssen announced a cell therapy-focused partnership with CBMG • Source: Shutterstock

More from Deals

More from Business